🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Deferred nephrectomy after ICI in mRCC—fresh data! 🔘Pathology showed 96% of specimens with necrosis, 21% of specimens showing no residual disease (pT0), and 21% exhibiting ≥95% necrosis. 🔘54% off systemic tx post-op 🔘Safe in selected patients ⚠️ Limitations: small cohort,

A new Stats, STAT! animated video explores interim analyses in clinical trials. During these evaluations of the data, researchers may assess safety, efficacy, and verify sample size assumptions, but these analyses require careful planning. Watch now: youtu.be/to81GKDsyc8

Trying to keep up with all the recent @kidneycancer biomarker developments? Check out our new review for all the latest updates. Brian Rini, MD Vanderbilt University Medical Center pubmed.ncbi.nlm.nih.gov/40240621/

Helpful data for our daily practice, since steroids are often part of the long drug list of our patients! Being more cautious with asymptomatic lab findings and cleaning med list is fundamental in cancer care…

Outcomes with novel combinations in non-clear cell #RCC: #ORACLE study. Deepak Kilari MD Medical College of Wisconsin joins Zach Klaassen Georgia Cancer Center to discuss research revealing differential responses to treatments based on histological subtypes, with specific combinations showing varying

Deferred cytoreductive nephrectomy after #ICI therapy in metastatic #RCC shows promising results, w/ 67% of pts having a partial radiological response & 54% discontinuing systemic therapy. Extensive necrosis may be a key marker for durable responses. doi.org/10.1093/oncolo…

Congrats Cristiane D Bergerot — always great to see 🇧🇷 making an impact in patient care!

Thanks UroToday.com grateful to work w Sam S. Chang MD, MBA, future is bright for patients as we incorporate highly effective ADC/IO combinations, sensitive and predictive biomarkers, novel intravesical tx leading to bladder preservation for more patients Bladder Cancer Advocacy Network

#ASCO25 ASCO 5-year follow-up of belzutifan in VHL disease shows durable tumor control and fewer surgeries. Vivek Narayan w/oral data June 1, 9:45 AM CDT, Hall D2 (Abstract 4507). Important long-term data for this rare cancer! Penn Medicine Penn Medicine - Abramson Cancer Center

This review evaluates different strategies for treating patients with advanced kidney cancer previously exposed to immunotherapy. ja.ma/4kwY2Uy Paulo Amaral, MD

I asked myself the same, once in some countries access to PARPi might be restricted.

6/24!

Tonight, every Brazilian — even deep down — was a Botafogo fan! Botafogo F.R. Paris Saint-Germain FIFA World Cup

#TumorBoardTuesday 🧑‍🎓Did you learn about HIF1 20+y ago❓ 🥸Well now we have agents to target🎯this key pathway👏 📢Join us Tuesday, 06-24-25 at 8PM ET as @Brian_rini & Paulo Amaral, MD🗣️the use of HIF⛔️in clear cell RCC #kidneycancer RT and bring others into the discussion‼️

#TumorBoardTuesday ➡️Before @Brian_rini & Paulo Amaral, MD🗣️the use of HIF inhibitors in advanced refractory clear cell renal cell carcinoma (ccRCC) #kidneycancer, tell us your connection to this medical🩺discussion 👇👇🏼👇🏾

Brian Rini, MD Paulo Amaral, MD ✅This #TumorBoardTuesday🗣️with Brian Rini, MD & Paulo Amaral, MD is provided by Integrity CE, LLC 👍Supported by ed grants from Exelixis, Ferring, Ipsen, Lilly, Janssen Scientific Affairs, Merck & Taiho Oncology🙏 Info about 🆓 CME: integrityce.com/tbt2025

Brian Rini, MD Paulo Amaral, MD Integrity CE, LLC #PreTest Q1️⃣ #TumorBoardTuesday Free #CME integrityce.com/TBT2025 B4⃣Brian Rini, MD & Paulo Amaral, MD 🗣️the use of HIF⛔️in clear cell RCC, test your🧠with these 2❓ 🧠 70-year-old with metastatic ccRCC progressed on axitinib + pembro → cabo. What would you use next❓

Brian Rini, MD Paulo Amaral, MD Integrity CE, LLC #PreTest Q2⃣#TumorBoardTuesday Free #CME 🧐What are the most common belzutifan-related AEs & what is the median onset in months for patients with RCC❓

Epogen is a HIF-regulated target gene so this is a classic on target effect. One interesting uncertainty is epogen regulation in the normal kidney versus the tumor.

Paulo Amaral, MD Brian Rini, MD Integrity CE, LLC Rana McKay, MD, FASCO Sumanta K. Pal, MD, FASCO Katy Beckermann Joseph Vento, MD, MS Miguel Zugman Toni Choueiri, MD Tom Powles Tian Zhang, MD, MHS KidneyCAN 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 jc Alan Tan Uromigos Laurence Albiges Andrey Soares Sahil Doshi Gabriel Aleixo James Brugarolas Yu-Wei Chen, MD, MS Hans Hammers #TumorBoardTuesday 😷What is "Breathtaking" is the complexity and the range of treatment options‼️ 🙏Thank you Brian Rini, MD and Paulo Amaral, MD for teaching us about the early world of targeting🎯HIF for #RCC